Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-02-01
Skovronsky Daniel Files Eli Lilly and Company (LLY) Form 4 - February 01, 2026
Skovronsky Daniel traded 18.3K LLY shares worth $5.9M in this Form 4 filing, reported to the SEC on 2026-02-01.
- Insider
- Skovronsky Daniel
- Issuer
- Eli Lilly and Company LLY · NYSE
- Filed
- Period
- 2026-02-01
- Accession
- 0001741474-26-000002
- Source
- Official filing on sec.gov ↗
Transactions (2)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Skovronsky Daniel | 2026-02-01 | Buy | 12.7K | $0.00 | $0.00 | Direct |
| Skovronsky Daniel | 2026-02-01 | Sell | 5.6K | $1.0K | $5.9M | Direct |
| Net change | +7.0K | −$5.9M | ||||
About Eli Lilly and Company
Eli Lilly and Company is a renowned pharmaceutical corporation that engages in the discovery, development, manufacturing, and marketing of pharmaceutical products worldwide. The company's core purpose is to create high-quality medications that address significant medical needs in areas such as oncology, immunology, neuroscience, and endocrinology. Eli Lilly is particularly noted for its pioneering work in diabetes care with products like insulin and for its innovative approach to treating complex health conditions. With a history dating back to 1876, the Indianapolis-based company blends scientific innovation with a commitment to improve patient outcomes. Eli Lilly’s role in the financial markets is significant due to its contributions to healthcare advancements and its influence on global pharmaceutical trends. The company's robust pipeline and emphasis on research and development underscore its potential to impact healthcare solutions and deliver sustainable growth. Its products and services are marketed globally, underlying its importance in the biopharmaceutical industry.
Track LLY insider activity
Get alerted when Eli Lilly and Company executives buy or sell their shares.